UTI Healthcare Fund · Regular · Growth
NAV
₹312.3361
as of 17 Jun 2026
Expense Ratio
2.27%
AUM
₹1,080 Cr
Lumpsum returns (CAGR)
- 1Y
- +11.01%
- 3Y
- +24.99%
- 5Y
- +14.42%
- Since Inception
- —
SIP returns (XIRR)
- 1Y
- +17.30%
- 3Y
- +17.38%
- 5Y
- +18.30%
- Since Inception
- —
Returns calculated from 16 September 2014 onwards due to a structural change in the scheme on that date. Earlier NAV history is preserved but excluded from multi-year return calculations. Periods spanning this date show —.
Risk Metrics
Trailing 1 year, annualised0.05
Sharpe Ratio
+0.03
Alpha
0.36
Beta
0.05
Sortino
14.83%
Std Dev
-16.02%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 Mar 2026Each sector links to the mutual funds most exposed to it.
Thinking about UTI Healthcare Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Compare with Similar Funds
Fund Details
Available transactions
Portfolio holdings
- 1Sun Pharmaceuticals Industries9.99%
- 2Ajanta Pharma Ltd.6.40%
- 3Lupin Ltd.5.92%
- 4Glenmark Pharmaceuticals Ltd.4.04%
- 5Apollo Hospitals Enterprise Lt3.73%
- 6Gland Pharma Ltd.3.46%
- 7Dr Reddys Laboratories Ltd.3.45%
- 8Divis Laboratories Ltd.3.42%
- 9Alkem Laboratories Ltd3.41%
- 10Fortis Healthcare Ltd.3.01%
Investment Objective
UTI Healthcare Fund · Regular · Growth invests in stocks from a specific sector or theme, offering concentrated exposure to a particular area of the economy. These funds carry sector-specific risks but can deliver significant returns when the underlying sector performs well.
About This Fund
UTI Healthcare Fund · Regular · Growth is a Sectoral / Thematic mutual fund offered by UTI Mutual Fund. The fund has been operational for over 26 years. It manages assets worth ₹1,080 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against BSE Healthcare TRI. The current expense ratio is 2.27%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations